semaglutide news today 2025 Novo Nordisk has announced that the FDA has approved the Wegovy® pill (once-daily oral 25 mg) as the first ever oral GLP-1 receptor agonist therapy for chronic weight management in adults Americans turn to risky unregulated

Retatrutide is not currently approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for routine clinical use in the UK

However, if you were on high-dose tirzepatide and switch to semaglutide, the reduced overall potency may result in somewhat less weight suppression long-term

The onset of Mounjaros effectiveness can vary, but some people may start to see weight loss within a few weeks of treatment

Recent reviews suggest GLP-1 receptor agonists may support ovulatory frequency in some women by addressing underlying metabolic dysfunction, though larger long-term fertility trials are still needed

Underexplored peptides that activate multiple receptors or signaling cascades may therefore be particularly well suited to modern therapeutic strategies that embrace controlled polypharmacology

Some research also suggests it may play a supportive role in: Liver health, Heart function, Metabolic conditions such as PCOS, Fatigue related to obesity